Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
Federal Trade Commission
Cipla
Fuji
Baxter
Boehringer Ingelheim

Generated: September 18, 2019

DrugPatentWatch Database Preview

Patent: 9,658,236

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,658,236
Title:Atypical hemolytic uremic syndrome (aHUS) biomarker proteins
Abstract: The disclosure provides biomarker proteins, a change in the concentration or activity level of which are associated with atypical hemolytic uremic syndrome (aHUS) or clinically meaningful treatment of aHUS with a complement inhibitor. Also provided are compositions and methods for interrogating the concentration and/or activity of one or more of the biomarker proteins in a biological fluid. The compositions and methods are useful for, among other things, evaluating risk for developing aHUS, diagnosing aHUS, determining whether a subject is experiencing the first acute presentation of aHUS, monitoring progression or abatement of aHUS, and/or monitoring response to treatment with a complement inhibitor or optimizing such treatment.
Inventor(s): McKnight; Susan Faas (Old Lyme, CT), Cofiell; Roxanne (Glastonbury, CT), Kukreja; Anjli (Fairfield, CT), Bedard; Krystin A. (N/A), Yan; Yan (Cheshire, CT)
Assignee: Alexion Pharmaceuticals, Inc. (New Haven, CT)
Application Number:15/287,162
Patent Claims:see list of patent claims

Details for Patent 9,658,236

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Alexion Pharm SOLIRIS eculizumab INJECTABLE; IV (INFUSION) 125166 001 2007-03-16   Try a Free Trial Alexion Pharmaceuticals, Inc. (New Haven, CT) 2033-08-07 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Johnson and Johnson
Queensland Health
Cantor Fitzgerald
QuintilesIMS
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.